Second Opinions Can Save Lives
Why Getting a Second Opinion for Cancer Can Save Your Life
Being told you have cancer is overwhelming, and it’s easy to feel pressured to start treatment right away. But getting a second opinion can make a huge difference—it may confirm the diagnosis, catch mistakes, or suggest new treatment options. For patients with stage 4 or hard-to-treat lung cancer, this extra step can open the door to advanced therapies and clinical trials not available everywhere.
Specialists at National Cancer Institute-designated centers look deeper than a single test. They review scans, biopsy slides, and genetic testing to match you with the best targeted therapy or immunotherapy. Many doctors welcome second opinions, and sometimes both teams can work together—giving you more support, not less.
Most importantly, a second opinion can give you peace of mind. Knowing your diagnosis and plan have been double-checked helps you move forward with confidence and focus on what matters most: your care and your life. (Source: Winship Magazine)
Read the complete article here >
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about practical guidance that can shape treatment decisions, like getting a second opinion and working with specialists. Explore genetic testing and treatment options such as targeted therapy, immunotherapy, and clinical trials. Join our community to connect with others who understand your experience.
Lung Cancer in Nonsmokers
Lung Cancer in Nonsmokers: The Truth, the Science, and Stories of Hope
Lung cancer is often treated like a “smoker’s disease,” but that stereotype is outdated—and it’s hurting people. Many patients have never smoked, and women under 65 are now seeing higher incidence rates than men in some age groups. What’s behind these cases? Often, the answer is biology: genetic mutations that can drive lung cancer even without traditional risk factors.
In this post, we’ll cover what’s driving lung cancer in nonsmokers (including RET-positive lung cancer and EGFR mutations), why stigma matters, what genetic testing can uncover, and how real patients are finding hope through research, advocacy, and community.
The Truth About Lung Cancer: It’s Not Just a Smoker’s Disease1
Lung cancer still carries a painful stigma. Many patients report feeling blamed or judged—by friends, family, and even medical professionals—because people assume smoking caused their disease. But anyone with lungs can get lung cancer, and no one deserves to be blamed for a diagnosis.
That stigma can do real harm. It’s been associated with delayed care, higher rates of depression, and lower screening rates—despite the fact that screening can catch lung cancer earlier, when treatment is often more effective. Shifting the narrative matters: lung cancer is a health issue, not a moral failing.
Lung Cancer in Women and Nonsmokers: What to Know2
Lung cancer diagnoses are declining overall, but a growing number of cases are being found in people who don’t fit the “typical” image—especially younger women and nonsmokers.
One reason some cases are missed or delayed is misdiagnosis. Younger nonsmoking women are sometimes told symptoms are asthma, bronchitis, or allergies, which can cost precious time. If you feel something is wrong, trust yourself. Persistent symptoms deserve follow-up, regardless of age or smoking history.
What’s Driving Lung Cancer in Nonsmokers?3
For many nonsmokers, lung cancer is driven by genetic mutations—changes inside cancer cells that help tumors grow. These are not the same as inherited risk (though inherited factors can play a role). Instead, they’re often tumor biomarkers that guide treatment.
This is why genetic testing (also called biomarker testing or molecular testing) is so important—especially for people with advanced lung cancer. It helps doctors match a patient to targeted therapy, which may be more effective and sometimes better tolerated than standard approaches alone.
Understanding RET-Positive Lung Cancer
One mutation that can drive lung cancer in nonsmokers is a RET fusion. RET-positive lung cancer is more common in never-smokers and can occur in younger patients, including women. It also may not show up through routine screening, which makes awareness and appropriate testing even more important.
Why it matters: If a tumor is RET-positive, a patient may be eligible for targeted treatments designed specifically to block RET-driven cancer growth. That can change the entire treatment plan—and outcomes.
Takeaway: If you or a loved one is diagnosed with lung cancer—especially stage 4 or hard-to-treat disease—ask your care team about biomarker testing early.
(Source: American Cancer Society, Yale Medicine, J Clin Oncol)
Read the complete article here
EGFR and Other Mutations: Why Testing Can Change Everything5
Mutations like EGFR are also more common in women and are seen at higher rates in certain populations, including Asian women. These biomarkers can open the door to targeted therapies that are specifically designed for cancers driven by those mutations.
The bottom line: lung cancer treatment is becoming more personalized. But personalization starts with testing.
How Research Is Accelerating Answers: The Lung Cancer Genetics Study6
A powerful genetics study is bringing hope to people facing lung cancer—especially nonsmokers and those with rare mutations. The Lung Cancer Genetics Study is collecting patient genetic and clinical data to help researchers:
- identify patterns in lung cancer among nonsmokers
- accelerate discoveries for rare mutations
- support more personalized treatment approaches
As more people participate and more data becomes available, researchers can move faster—and patients benefit from better-informed care.
Lung Cancer in Non-Smokers: Survivor & Patient Stories
Scientific progress matters—but so do stories. Real people are living proof that the lung cancer narrative is bigger than stigma.
From Remission to Recurrence: Karen’s Stage 4 Lung Cancer Journey
Karen was diagnosed with lung cancer at 47—a healthy, never-smoker with no family history—and after surgery, chemo, and eight clear years of scans, her cancer returned and became stage 4. Strengthened by new breakthroughs in lung cancer research, she continues to live fully. Karen’s story is a reminder that advances in treatment are giving patients more options, more time, and more hope.
Stage 4 Lung Cancer Veteran: Xavier Fights for Awareness
Air Force veteran Xavier Sanders was diagnosed with stage 4 lung cancer despite never smoking. He’s raising awareness about burn pit exposure, early detection, and support for service members. He’s not just fighting for himself. Xavier is advocating for younger airmen who may not know what symptoms to watch for or how to get the right care.
What You Can Do: Advocate for Yourself or Someone You Love
If you’re concerned about symptoms or navigating a diagnosis, these steps can help:
- Don’t dismiss persistent symptoms—especially a cough that won’t go away, shortness of breath, chest pressure, or unexplained weight loss
- Ask about lung cancer screening if you’re eligible
- If diagnosed, request biomarker testing early (RET, EGFR, and other drivers)
- Ask your doctor about targeted therapy, immunotherapy, and clinical trials when appropriate
- Seek community—support improves coping, confidence, and follow-through with care
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like lung cancer in nonsmokers by joining our community. Connect with others who understand your experience and gain access to trusted resources, medical updates, and invitations to supportive virtual gatherings.
References:
- https://www.mskcc.org/news/understanding-stigma-lung-cancer
- https://www.mskcc.org/news/lung-cancer-in-women-and-nonsmokers-what-to-know-about-symptoms-diagnosis-and-treatment
- https://happylungsproject.org/lung-cancer-risk-factors-understanding-its-causes-and-prevention/
Genetics Study Brings Lung Cancer Hope
Lung Cancer Genetics Study: New Hope Through Genetic Research
Learn how the Lung Cancer Genetics Study is collecting patient genetic and clinical data to accelerate discoveries, support personalized treatment, and bring new hope to families facing lung cancer.
A powerful new genetics study is offering fresh hope in the fight against lung cancer — especially for patients with rare mutations and those who’ve never smoked. The Lung Cancer Genetics Study, launched in 2024 by 23andMe and supported by nearly two dozen patient advocacy groups, is collecting genetic and clinical data from thousands of lung cancer patients to help uncover what drives this complex disease. It’s one of the first efforts of its kind to truly center patient voices from the beginning, ensuring that research reflects real-world experiences.
The project began with a friendship between two women living with lung cancer, Ilana Stromberg and Susan Troper Wojcicki, both mothers of five and determined to make a difference. Motivated by the lack of research and funding for lung cancer, especially RET-positive and other biomarker-driven subtypes, they envisioned a national lung cancer registry that could drive discoveries and lead to better, more personalized treatments. Susan’s passing in 2024 makes the study even more meaningful to those involved. Her legacy lives on through this groundbreaking initiative, which is expected to accelerate research and give families facing lung cancer a renewed sense of hope. (Source: 23andMe Blog)
Read the complete article here >
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like lung cancer genetics study by joining our community. Connect with others who understand your experience and gain access to trusted resources, upcoming events, medical updates, and invitations to supportive virtual gatherings.
Innovations Bring Hope to Lung Patients
New Lung Cancer Innovations Offering Hope to Patients
At Memorial Sloan Kettering, cutting-edge lung cancer care is changing lives—especially for those with advanced disease. Take Jen Cosgrove, a mother diagnosed with stage 4 lung cancer that had spread. Thanks to precise testing, doctors found her tumor had an ALK gene mutation, which responds well to targeted therapy called alectinib. Jen saw dramatic improvements within days and has been able to share important milestones with her children she once feared missing. MSK’s expert care, innovative treatments, and thorough diagnostics give patients like Jen hope and more time with their loved ones.
New Discoveries in Lung Cancer Detection
MSK researchers are also uncovering new types of lung cancer and better ways to detect it early. For example, they identified a rare form called atypical small cell lung carcinoma in younger patients who never smoked. Early detection remains critical, and MSK is developing noninvasive tools like the “E-nose,” a device that detects cancer-related chemicals in breath, which could make screening easier and less stressful. Lab studies on lung stem cells and tumor growth help scientists understand how cancer starts and grows, leading to better treatments. For patients facing lung cancer, these advances mean earlier diagnosis, more personalized care, and brighter hope for the future. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like lung cancer innovations. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Hope from Metastasis Research
Hope from Metastasis Research: New Advances for Stage 4 Cancer
Learn how metastasis research is uncovering how cancer spreads and resists treatment, including 3D patient models and new clinical trials offering hope for stage 4 cancer.
Metastasis is when cancer spreads from the original tumor to other parts of the body, and it’s often the toughest part to treat. Researchers at Memorial Sloan Kettering are studying how these metastatic cancer cells change and adapt to survive treatments. They found that metastatic cells can “shift” their identity to better survive, which helps explain why they become harder to stop over time.
At MSK, doctors are creating patient-based 3D models to better understand lung cancer spread and to test how different treatments work. There’s also a clinical trial exploring a drug that stops cancer cells in the brain and spine from stealing iron, which they need to grow and to avoid immune attack. This research is paving the way toward treatments that are more targeted and personalized.
For patients with late-stage or metastatic cancer, these advances offer hope for longer control of the disease and, one day, new ways to stop metastasis altogether. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like metastasis research, along with other important aspects of living with Stage 4 cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Precision Cancer Testing Brings New Hope
Precision Cancer Testing Brings New Hope for Stage 4 Cancer
At Memorial Sloan Kettering’s Center for Molecular Oncology, doctors use advanced testing to find the exact changes in a person’s cancer cells. This helps them choose treatments that specifically target those changes, giving patients a better chance at controlling their cancer. Over the past decade, tests like MSK-IMPACT® have made it possible to check for hundreds of genetic changes, even through simple blood tests, helping people with advanced or rare cancers find personalized therapies. But DNA testing doesn’t show everything, so new tests that look at how cancer cells use genes (called RNA tests) and even check all of a person’s genes (whole-genome sequencing) are coming soon. These tools aim to help patients who don’t respond to current treatments and could also guide immunotherapy, which uses the body’s immune system to fight cancer.
This kind of testing can also find inherited gene changes that increase cancer risk, helping families take steps to prevent cancer early. One inspiring example is patient Michael Wolff, a jazz pianist whose rare cancer was identified through molecular testing. Doctors found a gene mutation that led to a drug treatment which quickly stopped his symptoms and shrank his tumors. His success shows how precise testing can save lives and open the door to new treatments for cancers that were once very hard to treat. For patients with stage 4 or difficult cancers, these advances mean more hope for better, tailored care—and the chance for improved quality of life. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like precision cancer testing for stage 4 cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Cancer Vaccines Offer New Hope
Cancer Vaccines Offer New Hope: mRNA Breakthroughs for Stage 4 Cancer
Discover how therapeutic and personalized mRNA cancer vaccines are training the immune system to fight advanced cancers, with promising early clinical trial results.
Cancer vaccines, once considered a distant dream, are becoming a hopeful reality thanks to groundbreaking research inspired by the success of COVID-19 mRNA vaccines. Unlike traditional vaccines designed to prevent illnesses, therapeutic cancer vaccines teach the body’s own immune system how to recognize and attack cancer cells. Memorial Sloan Kettering (MSK) researchers, building on ideas first imagined over a century ago, have significantly advanced these vaccines. Dr. David Scheinberg, a leading researcher at MSK, explains that new technologies now allow vaccines to target multiple proteins specific to cancer cells, making treatments more effective and reducing side effects compared to chemotherapy and radiation.
One promising area is personalized mRNA cancer vaccines, custom-made for each patient based on their tumor’s unique characteristics. Early trials, particularly in pancreatic cancer, have shown encouraging results, with vaccinated patients’ immune cells remaining active for years. Additionally, MSK researchers are developing off-the-shelf vaccines targeting common cancer markers, such as WT1, found in leukemia and ovarian cancer. These vaccines could soon offer accessible, affordable options for many patients. The rapid progress in cancer vaccine development at MSK offers genuine optimism, especially for patients fighting advanced or hard-to-treat cancers. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like mRNA cancer vaccines for stage 4 cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Consider Donating to Advance Research
RET-Positive Lung Cancer Research: How Tissue Donation Helps
RET-positive lung cancer is rare, and researchers need better lab models to study it. Learn how donating tumor tissue can help create cell lines and advance targeted treatments.
RET-positive lung cancer is a rare type of cancer driven by a change in a gene called RET, which stands for “rearranged during transfection.” This gene helps control how cells grow and divide. When it fuses with another gene or mutates, it can cause cancer to grow and spread, especially in certain lung and thyroid cancers. Because RET changes are so rare, researchers don’t have enough lab models called cancer cell lines. That makes it harder to study how the cancer behaves and becomes resistant to treatment.
One powerful way patients can help is by donating tumor tissue during a biopsy or surgery. That tissue can be used to grow RET-positive cancer cells in the lab, giving scientists tools to test new treatments and develop better, more personalized options. Thanks to the generosity of several RET patients, four new cancer cell lines are now being developed. If you’re a patient, talk to your care team about donating. Your gift could move research forward and help bring better treatments to others living with RET-driven cancer. (Source: The Happy Lungs Project)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like RET-positive lung cancer research. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
New Lung Cancer Treatments Show Real Promise
New 2025 Research Brings Hope for Advanced Lung Cancer
New research shared in 2025 brings hope for people with advanced non-small cell lung cancer. Scientists presented several treatment updates that are helping patients live longer with fewer side effects. One medicine, aumolertinib, helped slow cancer growth—especially when combined with chemotherapy. Aumolertinib is a targeted therapy that blocks the EGFR protein, which drives tumor growth in certain lung cancers. When added to chemotherapy, it has been shown to significantly delay cancer progression and is generally well tolerated. Another drug, JYP0322, worked well for people with a rare type of lung cancer, even when the cancer had spread to the brain. JYP0322 is an investigational ROS1 inhibitor designed to cross the blood-brain barrier, making it effective against brain metastases. Early trials showed promising responses in patients who had previously received other ROS1-targeted treatments.
Other promising treatments are helping people whose cancer carries uncommon genetic changes. A pill called zongertinib helped many patients and caused fewer side effects than older drugs. Zongertinib targets HER2-mutated lung cancer, which is rare but often aggressive. Clinical studies showed it shrinks tumors effectively and causes fewer side effects compared with older treatments. Another new medicine, zoldonrasib, showed early success in shrinking tumors in patients whose cancer had stopped responding to other treatments. While one immune-based drug didn’t work as well as hoped, researchers believe it still has potential. Zoldonrasib, is designed for cancers with the KRAS G12D mutation, a mutation that was historically difficult to treat. Early trial results indicate it can shrink tumors in patients whose cancer no longer responds to standard therapies. Overall, the message is clear: more personalized and effective treatments are on the horizon. (Source: American Association for Cancer Research)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like advanced lunch cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Caroline’s Story: Facing Lung Cancer with Family and Hope
Caroline’s Lung Cancer Genetic Mutation Story
Caroline, a nurse practitioner from Louisiana, knows the impact of lung cancer firsthand due to her family’s experience. Several relatives who never smoked developed lung cancer, prompting genetic testing that revealed an EGFR gene mutation affecting Caroline, her mother, and grandmother. Shortly after having her baby, Caroline’s own lung screening showed nodules, leading to surgery and challenging complications that required multiple hospitalizations. She eventually found a supportive medical team closer to home at MD Anderson, where she continues to receive regular screenings.
Embracing a positive outlook, Caroline draws strength from her family and friends and actively raises awareness about genetic mutations in lung cancer, inspired by her meeting with Dr. Geoff Oxnard, hoping her experience will encourage and inform others. (Source: EGFR Resisters)
9 Common Questions About Genetic Testing for Cancer
For patients facing stage 4 lung cancer or those with a strong family history of cancer, genetic testing can offer clarity, guidance, and hope. About 10% of cancers are hereditary, meaning they are driven by inherited gene mutations that can be passed through families. Testing for these mutations, such as BRCA1, BRCA2, and others linked to lung or related cancers, helps doctors understand a patient’s personal cancer risk and may also guide treatment choices—especially for targeted therapies.
Importantly, having a gene mutation doesn’t mean you’ll definitely get cancer, but it does raise your risk. If you already have cancer, genetic testing can sometimes influence treatment decisions, like choosing one type of chemotherapy or surgery over another. For those with a family history, testing can alert relatives to start earlier cancer screenings or preventive measures. Bringing a detailed family history to your genetic counseling appointment can be a valuable first step.
Knowing your genetic risk empowers you to take proactive steps—whether that’s enrolling in clinical trials, pursuing early screening, or helping your children understand their potential risks. While we can’t change our genes, we can change how we respond to what they tell us. (Source: Mayo Clinic)
